	US 11,753,642 B2
	Nucleic acids for inhibiting expression of C3 in a cell
Verena Aumiller, Berlin (DE); Lucas Bethge, Potsdam (DE); Judith Hauptmann, Berlin (DE); Marie Wikström Lindholm, Malmö (SE); and Adrien Weingärtner, Berlin (DE)
Assigned to SILENCE THERAPEUTICS GMBH, Berlin (DE)
Filed by SILENCE THERAPEUTICS GMBH, Berlin (DE)
Filed on May 26, 2022, as Appl. No. 17/825,376.
Application 17/825,376 is a continuation of application No. 17/612,120, previously published as PCT/EP2020/073904, filed on Aug. 26, 2020.
Prior Publication US 2023/0024926 A1, Jan. 26, 2023
Int. Cl. C12N 15/113 (2010.01)

CPC C12N 15/113 (2013.01) [C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/3125 (2013.01); C12N 2310/351 (2013.01); C12N 2320/30 (2013.01)]

29 Claims

1. A double-stranded nucleic acid for inhibiting expression of complement component C3, wherein the nucleic acid comprises a first strand and a second strand, wherein:

the first strand sequence comprises a sequence of 5′ (vp)-mU fU mG fU mA fG mU fA mG fC mG fG mA fU mC fU mU fG (ps2) mG 3′ (SEQ ID NO: 409) and the second strand sequence comprises a sequence of 5′mC (ps2) mC mA mA mG mA fU fC fC mG mC mU mA mC mU mA mC mA (ps2) mA 3′ (SEQ ID NO: 423).